Table 1.
Experienced -Resistant N = 20 |
Experienced -Non-Resistant N = 211 |
Naïve -Resistant N = 165 |
Naïve -Non-Resistant N = 1427 |
p-Value 1 | |
---|---|---|---|---|---|
Female; n (%) | 9 (45%) | 69 (33%) | 32 (19%) | 223 (16%) | <0.01 |
Median age (years); (IQR) | 34 (28–39) | 34 (27–42) | 30 (25–41) | 29 (25–38) | <0.01 |
Transmission risk *; n (%) Heterosexual cisgender women MSM Heterosexual cisgender men PWID |
8 (40%) 5 (20%) 5 (20%) 1 (0.5%) |
62 (29%) 83 (39%) 34 (16%) 13 (6%) |
30 (18%) 82 (49%) 35 (21%) 3 (1.8%) |
204 (14%) 838 (59%) 252 (18%) 26 (1.8%) |
< 0.01 |
Mean CD4+ T cell count; cells/mm3 (IQR) | 223 (58–410) | 143 (53–343) | 244 (94–459) | 237 (91–413) | 0.31 |
Education; n (%) Elementary or lower High school or higher Unknown |
8 (40%) 12 (60%) 0 (0%) |
62 (29%) 141 (67%) 8 (4%) |
31 (19%) 128 (77%) 6 (4%) |
217 (15%) 1159 (81%) 51 (3.5%) |
<0.01 |
Occupation; n (%) Employed Unemployed Student |
4 (20%) 16 (80%) 0 (0%) |
81 (40%) 107 (53%) 15 (7%) |
88 (51%) 63 (37%) 21 (12%) |
824 (54%) 532 (35%) 154 (10%) |
<0.01 |
Median time of follow-up (years); (IQR) | 1.93 (0.85–2.08) | 1.91 (1.51–2.04) | 1.86 (1.66–2.05) | 1.87 (1.60–2.01) | 0.74 |
First ART regimen group; n (%) Based on EFV Integrase Inhibitors Protease Inhibitors Other |
9 (45%) 3 (15%) 7 (35%) 1 (5%) |
120 (58%) 15 (7%) 68 (33%) 4 (2%) |
100 (64%) 50 (33%) 4 (2%) 1 (1%) |
907 (67%) 366 (27%) 70 (5%) 3 (0.2%) |
<0.01 |
1 The p-value compares the distribution of variables in each group, from Kruskal–Wallis, chi-squares, or fisher test according with the type of variable. * PWID: people who inject drugs includes 43 participants, 39 of them men and 4 women; 26 in the naïve + non-resistant group; 13 in the experienced + non-resistant; 1 in the experienced + resistant; and 3 in the naïve resistant. The missing information for risk of transmission was 1 for experienced + resistant, 19 in the experienced +non-resistant, 107 in the naive-resistant and 15 in the naïve + non-resistant (n = 142).